GLYC - GlycoMimetics plummets 77% as phase 3 leukemia therapy uproleselan fails May, 06 2024 08:39 AM GlycoMimetics Inc. 2024-05-06 08:39:50 ET More on GlycoMimetics GlycoMimetics: Is No News Bad News? GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript GlycoMimetics Can Become A Game Changer In Blood Cancers Seeking Alpha’s Quant Rating on GlycoMimetics Historical earnings data for GlycoMimetics For further details see: GlycoMimetics plummets 77% as phase 3 leukemia therapy uproleselan fails